Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Aug. 20, 2018. Bradley Thompson.

Executive Summary

Attorney and industry advocate Bradley Merrill Thompson argues in a recent Medtech Insight article that US FDA is pursuing expanded authorities for collecting and acting on post-market device data without congressional authorization. Read one of Thompson's recommendations here.

 
"We need Congress to lay out a system that specifies both the process through which CDRH decides to make use of adverse publicity, and standards that define the circumstances in which the center can use that tactic." – Bradley Thompson, attorney, Epstein, Becker & Green


Click here for a free trial of Medtech Insight

Topics

UsernamePublicRestriction

Register

MT123143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel